Sichuan Hongminbosi is a subsidiary of Sichuan Biomedical Industry Group Co., Ltd. and was founded in January 2013 with Chengdu Baiyu Pharmaceutical Co., Ltd.'s shareholding, and its subsidiary, Sichuan Yujian Pharmaceutical Co., Ltd. focuses on the development and production of API. Covering an area of 53,000 square meters, with a total planned investment of 600 million yuan, and the current investment of 550 million yuan, in line with the EU cGMP / U.S. FDA cGMP standards Hongbo Pharmaceuticals focuses on the operation of the pharmaceutical entity industry, covering the business of drug research and development, manufacturing, distribution and sales of the entire industrial chain, with injectables, lyophilized powder injection, tablets, capsules and other high-end dosage forms and production capacity of APIs.

It was officially put into operation in March 2018, with small volume injection/lyophilized powder injection/solid preparation workshops, the factory now has 21 drug approval numbers, one small volume injection production line with a design capacity of 100 million pcs, and two lyophilized powder injection production lines with a design capacity of 80 million pcs. Oral solid dosage one workshop production line, tablet design capacity of 200 million tablets, capsule design capacity of 100 million capsules.